MA-VERACODE
2.4.2024 09:31:35 CEST | Business Wire | Press release
Veracode, a global leader in application risk management, today announced the acquisition of Longbow Security, a pioneer in security risk management for cloud-native environments. The acquisition marks the next exciting phase of Veracode, underscoring the company’s commitment to help organizations effectively manage and reduce application risk across the growing attack surface.
The integration of Longbow into Veracode enables security teams to discover cloud and application assets quickly and easily assess their threat exposure using automated issue investigation and root cause analysis. Longbow provides a centralized view of risk for cloud assets and applications, thereby simplifying complex workflows, enabling faster and more effective remediation, and improving overall security posture. The result is reduced risk and fewer vulnerabilities in applications and cloud infrastructures.
Increased adoption of cloud infrastructure, combined with developers taking on more responsibility for the creation, deployment, and security of software, has introduced operational complexity. Organizations now require a deeper understanding of their risk profile within changing environments and a continuous security feedback loop throughout the software development life cycle.
“Security teams are drowning in alerts that lack sufficient detail on the level of business risk, degree of exploitability of a flaw, and specific code-level insight to keep pace with remediation requirements. As a result, risk continues to accumulate,” said Brian Roche, Chief Product Officer at Veracode. “With the combination of Veracode and Longbow, teams can get a comprehensive view of their risk, automate prioritization of what matters most, and, with Veracode Fix, automate remediation of code security flaws.”
Longbow and Veracode Simplify Cloud Application Security for Overloaded Teams
With 71 percent of organizations shouldering the burden of “security debt” (flaws in applications that remain unfixed for one year), teams must act quickly to reduce their threat exposure. Yet, sufficient visibility and alert fatigue continue to plague cloud and application security professionals today. With Longbow, Veracode customers can address these challenges in four ways:
- Unified visibility of risk across applications, code, and cloud. This gives teams insight to tackle significant issues that matter most to the business.
- Orchestrated remediation from code to cloud, enabling teams to prioritize and remediate with Veracode’s AI-driven fix capabilities.
- Actionable insights with ‘Best Next Action’ advice, so customers can conduct a root cause analysis and pinpoint the best path to remediation.
- Continuous monitoring and assessment via real-time vulnerability discovery across application portfolios and runtime environments, meaning customers know exactly what is running and where.
Derek Maki, Co-Founder & Chief Product Officer at Longbow said, “We founded Longbow with a mission to simplify an increasingly complex application security risk management process and help organizations reduce risk at scale. By joining forces with Veracode, our combined solutions provide unmatched visibility, automation, and remediation capability for security and engineering teams. We are excited to take cloud-native application security to the next level.”
“This is the perfect fit for Longbow,” said Dayne Myers, Co-founder & Chief Executive Officer of Longbow. “After careful consideration, we believe that our technology and team align seamlessly with Veracode's vision, making this the best choice for Longbow’s future."
“We’re thrilled to welcome Longbow to Veracode and expand our platform capabilities with industry-leading application security posture management for today’s enterprise requirements,” closed Sam King, Chief Executive Officer at Veracode. “The integration of our solutions provides organizations with a holistic application risk management platform that spans code to cloud. Veracode combined with Longbow advances the field of application security and enables customers to secure their increasingly complex application landscape more efficiently.”
Longbow is available immediately. To learn more about the platform, visit the Longbow website. Read the blog for information on the acquisition.
About Veracode
Veracode is intelligent software security. The Veracode Software Security Platform continuously finds flaws and vulnerabilities at every stage of the modern software development lifecycle. Using powerful AI trained on a carefully curated, trusted dataset from experience analyzing trillions of lines of code, Veracode customers fix flaws faster with high accuracy. Trusted by security teams, developers, and business leaders from thousands of the world’s leading organizations, Veracode is the pioneer, continuing to redefine what intelligent software security means.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and Twitter.
Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401671481/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
